8-K: RxSight Reports Q3 Revenue Decline Amid Strategic Realignments

RxSight, Inc. announced a 14% decrease in third-quarter 2025 revenue to $30.3 million, despite a 6% increase in Light Adjustable Lens procedure volume, while narrowing full-year revenue guidance and raising gross margin expectations.

Summary

• Third quarter 2025 revenue was $30.3 million, a 14% decrease compared to $35.3 million in the third quarter of 2024.
• Light Adjustable Lens (LAL/LAL+) procedure volume increased by 6% with 26,045 units sold.
• Light Delivery Device (LDD) sales decreased by 68%, with only 25 units sold.
• The installed base of LDDs grew by 25% year-over-year to 1,109 units as of September 30, 2025.
• Gross margin improved significantly to 80%, an increase of 844 basis points from 71% in Q3 2024, primarily due to a favorable shift in product mix towards LAL sales.
• Total operating expenses increased by 6% to $36.4 million, reflecting investments in LAL sales volume and R&D.
• Net loss for the quarter was $(9.8) million, or $(0.24) per basic and diluted share, compared to a net loss of $(6.3) million, or $(0.16) per share in Q3 2024.
• Adjusted net loss was $(1.7) million, or $(0.04) per share, a decline from an adjusted net gain of $0.2 million, or $0.01 per share, in Q3 2024.
• Cash, cash equivalents, and short-term investments remained stable at $227.5 million as of September 30, 2025.
• Full-year 2025 revenue guidance was narrowed to $125.0 million to $130.0 million, implying an 11% to 7% decrease compared to 2024.
• Full-year 2025 gross margin guidance was raised to 76% to 77%, an increase from the previous range of 72% to 74%.
• Operating expense guidance for 2025 was reiterated at $145.0 million to $155.0 million, including increased non-cash stock-based compensation expense of $30.0 million to $32.0 million.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to a significant revenue decline and increased net loss in Q3, alongside full-year revenue guidance that still implies a decrease. While gross margin improvement and LAL procedure growth are positive, they are overshadowed by the overall financial performance and sharp drop in LDD sales. Strategic initiatives are underway, but their impact on reversing the negative trends is yet to be fully realized.

Positives

• Gross margin significantly increased to 80% in Q3 2025, up 844 basis points from 71% in Q3 2024, driven by a favorable product mix towards LAL sales.
• Light Adjustable Lens (LAL/LAL+) procedure volume increased by 6% compared to the third quarter of 2024, indicating continued adoption of the core product.
• The installed base of Light Delivery Devices (LDDs) grew by 25% year-over-year to 1,109 units, suggesting a growing foundation for future LAL sales.
• Full-year 2025 gross margin guidance was raised to 76%-77%, indicating confidence in continued margin improvement.
• Strategic realignment of the U.S. commercial organization and launch of new practice development programs aim to resume LAL procedure growth.

Negatives

• Total revenue decreased by 14% to $30.3 million in Q3 2025 compared to Q3 2024.
• Light Delivery Device (LDD) sales saw a substantial 68% decrease, impacting overall revenue.
• Net loss widened to $(9.8) million in Q3 2025 from $(6.3) million in Q3 2024.
• Adjusted net loss shifted from a gain of $0.2 million in Q3 2024 to a loss of $(1.7) million in Q3 2025.
• Operating expenses increased by 6% to $36.4 million, contributing to the larger net loss.
• Full-year 2025 revenue guidance, even after narrowing, still implies an 11% to 7% decrease compared to 2024.

Risks

• The company refers to specific risk factors that may be found in the section entitled Part II, Item 1A (Risk Factors) in the Quarterly Report on Form 10-Q for the three months ended September 30, 2025, filed with the Securities and Exchange Commission (SEC) on or about the date hereof.

Future Outlook

The company narrowed its full-year 2025 revenue guidance to a range of $125.0 million to $130.0 million, which still implies a decrease of 11% to 7% compared to 2024. However, it raised its full-year gross margin guidance to 76% to 77%, reflecting an anticipated increase of 529 to 629 basis points compared to 2024. Operating expenses are projected to remain in the range of $145.0 million to $155.0 million, with non-cash stock-based compensation expected to be $30.0 million to $32.0 million. Management anticipates a measured pace of stabilization and recovery in procedure trends, driven by a unified commercial team and growing recognition of the company's clinical value.

Management Comments

• "Procedure trends during the quarter reflected a measured pace of stabilization and recovery, and we are encouraged by the engagement across the field as our unified commercial team deepens customer relationships."
• "The enthusiasm we saw at AAO and ESCRS, the two largest ophthalmic conferences in the U.S. and Europe, underscored the continued interest from surgeons, highlighted by the quality of peer-to-peer discussions and the growing recognition of RxSight's clinical value to both patients and practices."

Industry Context

RxSight operates in the ophthalmic medical device sector, specifically focusing on cataract surgery with its unique Light Adjustable Lens technology. The reported increase in LAL procedure volume suggests continued surgeon and patient interest in advanced, customizable vision correction post-cataract surgery. However, the significant decline in Light Delivery Device (LDD) sales indicates a potential saturation or slower adoption rate for new installations, shifting the company's revenue mix more towards recurring lens sales. The strategic realignment and international expansion efforts are consistent with a company seeking to deepen market penetration and explore new growth avenues in a competitive and innovation-driven medical device industry.

Comparison to Industry Standards

• NA

Management Changes

Stakeholder Impact

• Shareholders: Face decreased revenue and increased net loss, potentially impacting stock performance, though improved gross margin and strategic initiatives offer long-term potential.
• Customers (Ophthalmic Practices/Surgeons): Benefit from deeper LAL practice integration and new development programs, potentially enhancing their ability to offer customized vision solutions.
• Patients: Continue to benefit from the unique post-surgery adjustability of the Light Adjustable Lens system for high-quality customized vision.
• Employees: Impacted by the realignment of the U.S. commercial organization, potentially leading to new roles or responsibilities within integrated clinical and sales teams.

Next Steps

• Host a conference call on November 5, 2025, at 1:30 p.m. Pacific Time to discuss Q3 2025 financial results.
• Continue to execute on the realigned U.S. commercial organization to resume growth in LAL procedures.
• Further implement practice development and clinical engagement programs to drive targeted practice engagement.
• Develop and execute international commercial strategy under the new Executive Vice President, International.
• File the Quarterly Report on Form 10-Q for the three months ended September 30, 2025, with the SEC.

Key Dates

Recommendation

The company presents a mixed financial picture with a significant revenue decline and increased net loss in Q3 2025, which are concerning. However, the strong improvement in gross margin, continued growth in LAL procedure volume, and a growing installed LDD base indicate underlying product strength and operational efficiency. The strategic realignments and appointment of an EVP International suggest proactive measures to address challenges and drive future growth. The raised full-year gross margin guidance is a positive signal. Given the current headwinds in revenue but strategic efforts and margin improvements, a 'hold' recommendation is appropriate as the company navigates its recovery and growth initiatives. Investors should monitor the effectiveness of the commercial realignment and international expansion.

Keywords

ophthalmic medical device, cataract surgery, Light Adjustable Lens, LAL, Light Delivery Device, LDD, intraocular lens, IOL, financial results, Q3 2025, revenue, gross margin, net loss, RxSight